hCAIX/XII-IN-6

立即咨询

hCAIX/XII-IN-6

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

hCAIX/XII-IN-6 是一种碳酸酐酶 (CA) 抑制剂，具有口服活性。hCAIX/XII-IN-6 抑制人 CA 亚型 hCA I、II、IV、IX 和 XII，K_i值分别为 6697 nM、2950 nM、4093 nM，4.1 nM 和 7.7 nM。hCAIX/XII-IN-6 可用于类风湿关节炎（RA）的研究。

生物活性

hCAIX/XII-IN-6 is an orally activecarbonic anhydrase(CA)inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII withK_ivalues of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA)^[1].

IC₅₀& Target^[1]

hCA II

2950 nM (Ki)

hCA IX

4.1 nM (Ki)

hCA XII

7.7 nM (Ki)

体外研究
(In Vitro)

hCAIX/XII-IN-6 has inhibition activitr for human CA isoforms hCA I, II, IV, IX, and XII with K_ivalues of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively^[1]^[1].
hCAIX/XII-IN-6 (150 μM) exhibits a weaker H2S releas^[1].

体内研究
(In Vivo)

hCAIX/XII-IN-6 (oral; 1, 10, 30 mg/kg; single) completely reverts the pain state 45 min after administration and enhances antihyperalgesic effect in vivo^[1].

Animal Model:	adjuvant-induced arthritis rat model^[1]
Dosage:	1, 10, 30 mg/kg
Administration:	oral, single
Result:	Evoked an antihypersensitivity effect in a dose-dependent manner. Reduced spontaneous pain in a dose-dependent manner with a peak of efficacy between 30 and 45 min.

分子量

601.74

Formula

C₂₆H₂₃N₃O₆S₄

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.